Figure 4
From: Comparison of amplification enzymes for Hepatitis C Virus quasispecies analysis
Comparison of quasipecies genetic diversity (assessed by HMR, Panel A) and complexity (panel B) scores generated with Taq or HF-2 polymerases, in 20 HALT-C samples who were HCV RNA negative (N = 6) or HCV RNA positive (N = 14) at week 20 (W20) of pegylated IFN plus ribavirin therapy. The box plots represent the means and ranges of the HMR and complexity scores for 400 HVR1 clones amplified by each polymerase, for a total of 800 clones (20 patients × 20 clones/patient × 2 enzymes). Error bars represent standard deviations. Wilcoxon Signed Ranks tests determined that the differences between enzymes and patient groups were not statistically significant.